Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Improved survival outcome in SARs-CoV-2 (COVID-19) Acute Respiratory Distress Syndrome patients with Tocilizumab administration

Nafisa Wadud, Naim Ahmed, Mannu Shergil, Maida Khan, Murali Krishna, Aamir Gilani, Samer El Zarif, Jodi Galaydick, Karthika Linga, Shravan Koor, Julia Galea, Lauren Stuczynski, Maria B Osundele
doi: https://doi.org/10.1101/2020.05.13.20100081
Nafisa Wadud
1Orange Regional Medical Center (All authors)
2Department of Internal Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Naim Ahmed
1Orange Regional Medical Center (All authors)
2Department of Internal Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mannu Shergil
1Orange Regional Medical Center (All authors)
2Department of Internal Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maida Khan
1Orange Regional Medical Center (All authors)
2Department of Internal Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Murali Krishna
1Orange Regional Medical Center (All authors)
3Department of Pulmonary, Critical Care and Sleep Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mkrishna@ghvhs.org
Aamir Gilani
1Orange Regional Medical Center (All authors)
3Department of Pulmonary, Critical Care and Sleep Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samer El Zarif
1Orange Regional Medical Center (All authors)
3Department of Pulmonary, Critical Care and Sleep Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jodi Galaydick
1Orange Regional Medical Center (All authors)
3Department of Pulmonary, Critical Care and Sleep Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karthika Linga
1Orange Regional Medical Center (All authors)
3Department of Pulmonary, Critical Care and Sleep Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shravan Koor
1Orange Regional Medical Center (All authors)
3Department of Pulmonary, Critical Care and Sleep Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julia Galea
1Orange Regional Medical Center (All authors)
4Department of Pharmacy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lauren Stuczynski
1Orange Regional Medical Center (All authors)
4Department of Pharmacy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria B Osundele
1Orange Regional Medical Center (All authors)
4Department of Pharmacy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background The novel human coronavirus, severe acute respiratory syndrome coronavirus-2 (SARs-CoV-2), was declared a global pandemic by the World Health Organization on March 11, 2020. Hence, there is an urgency to find effective treatment. Of those patients afflicted in the United States, many have required treatment with ventilator secondary to acute respiratory distress syndrome (ARDS). Data are needed regarding the benefit of treatment and prevention of the cytokine storms in COVID-19 patients with Tocilizumab.

Methods Clinical outcomes data for patients admitted to Orange Regional Medical Center with confirmed COVID-19 from Mar 15, 2020 to Apr 20, 2020 were identified through electronic health record chart review. We conducted a retrospective case-control study in confirmed COVID 19 positive patients with ARDS requiring mechanical ventilation and compared outcome in terms of mortality and length of stay amongst those who received Tocilizumab as treatment modality opposed to those that did not.

Results A total of 94 patients with COVID-19 ARDS were analyzed. 44 were in the study group and 50 in the control group. We tried to match both group as close as possible in terms of age, sex, BMI and HS score-calculated using inflammatory markers-ferritin, triglycerides, AST and fibrinogen. The median age was 55.5 years in the study group and 66 in the control group, difference was not statistically significant. Average HS score was 114 in the Tocilizumab group and 92 in the control group, difference was statistically significant with P<0.0001. Also, the patients in the study group had elevated levels of IL-6, triglycerides, AST, ferritin which were statistically significant with p < 0.0001 when compared to the control group. Length of stay was longer, average 17.9 days in the Tocilizumab. Survival rate was much lower at 48 % in the control group and 61.36 % in patients who received Tocilizumab with significant P value of < 0.00001. The number needed to treat (NNT) was 7.48, if we treat 8 patients with Tocilizumab, 1 will not die.

Conclusion Cytokine Release Syndrome (CRS) occurs in a large number of patients with severe COVID-19, which is also an important cause of death. IL-6 is the key molecule of CRS, so IL-6R antagonist Tocilizumab may be of value in improving outcomes. In our study Tocilizumab group seemed to have improved survival outcome. Results have to be interpreted with caution since this is a retrospective study and mortality is affected by multiple, confounding factors. We await the results of ongoing randomized controlled trials to definitely answer the question of whether Tocilizumab improves survival in COVID-19 ARDS patients.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

No external funding was received.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data was obtained from electronic medical record review.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted May 16, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Improved survival outcome in SARs-CoV-2 (COVID-19) Acute Respiratory Distress Syndrome patients with Tocilizumab administration
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Improved survival outcome in SARs-CoV-2 (COVID-19) Acute Respiratory Distress Syndrome patients with Tocilizumab administration
Nafisa Wadud, Naim Ahmed, Mannu Shergil, Maida Khan, Murali Krishna, Aamir Gilani, Samer El Zarif, Jodi Galaydick, Karthika Linga, Shravan Koor, Julia Galea, Lauren Stuczynski, Maria B Osundele
medRxiv 2020.05.13.20100081; doi: https://doi.org/10.1101/2020.05.13.20100081
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Improved survival outcome in SARs-CoV-2 (COVID-19) Acute Respiratory Distress Syndrome patients with Tocilizumab administration
Nafisa Wadud, Naim Ahmed, Mannu Shergil, Maida Khan, Murali Krishna, Aamir Gilani, Samer El Zarif, Jodi Galaydick, Karthika Linga, Shravan Koor, Julia Galea, Lauren Stuczynski, Maria B Osundele
medRxiv 2020.05.13.20100081; doi: https://doi.org/10.1101/2020.05.13.20100081

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Intensive Care and Critical Care Medicine
Subject Areas
All Articles
  • Addiction Medicine (243)
  • Allergy and Immunology (525)
  • Anesthesia (125)
  • Cardiovascular Medicine (1434)
  • Dentistry and Oral Medicine (220)
  • Dermatology (158)
  • Emergency Medicine (292)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (589)
  • Epidemiology (10333)
  • Forensic Medicine (6)
  • Gastroenterology (533)
  • Genetic and Genomic Medicine (2653)
  • Geriatric Medicine (255)
  • Health Economics (499)
  • Health Informatics (1744)
  • Health Policy (791)
  • Health Systems and Quality Improvement (681)
  • Hematology (269)
  • HIV/AIDS (571)
  • Infectious Diseases (except HIV/AIDS) (12119)
  • Intensive Care and Critical Care Medicine (650)
  • Medical Education (276)
  • Medical Ethics (83)
  • Nephrology (291)
  • Neurology (2483)
  • Nursing (145)
  • Nutrition (381)
  • Obstetrics and Gynecology (497)
  • Occupational and Environmental Health (569)
  • Oncology (1335)
  • Ophthalmology (403)
  • Orthopedics (152)
  • Otolaryngology (239)
  • Pain Medicine (172)
  • Palliative Medicine (51)
  • Pathology (345)
  • Pediatrics (786)
  • Pharmacology and Therapeutics (334)
  • Primary Care Research (297)
  • Psychiatry and Clinical Psychology (2421)
  • Public and Global Health (5031)
  • Radiology and Imaging (902)
  • Rehabilitation Medicine and Physical Therapy (536)
  • Respiratory Medicine (688)
  • Rheumatology (309)
  • Sexual and Reproductive Health (257)
  • Sports Medicine (246)
  • Surgery (300)
  • Toxicology (45)
  • Transplantation (141)
  • Urology (108)